Filter by Year
Acer Therapeutics Forms Scientific Advisory Board
Inaugural team of experts to provide valuable insights and guidance on NDA filing of the company’s lead product, VASEBRA™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome, and pivotal clinical studies of ACER-001 in MSUD and UCD CAMBRIDGE, Mass., December 20, 2016 – Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases […]
Read MoreAcer Therapeutics Obtains Exclusive License to Celiprolol Pivotal Clinical Data from AP-HP
Company obtains exclusive rights to NDA-enabling clinical data of the company’s lead product, VASEBRA™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) CAMBRIDGE, Mass., December 13, 2016 – Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, today announced the signing of an agreement with the […]
Read MoreAcer Therapeutics Closes $8.15 Million Series B Financing
Financing will support the regulatory filing for the company’s lead product, VASEBRA™, for the treatment of Vascular Ehlers – Danlos Syndrome, as well as pivotal clinical studies for ACER-001 in MSUD and UCD CAMBRIDGE, MA, May 9, 2016 – Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical […]
Read MoreAcer Therapeutics Appoints Robert D. Steiner, M.D., as Chief Medical Officer
Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, appointed Robert Steiner, M.D. to Chief Medical Officer. In this role, Dr. Steiner will be responsible for driving strategy for and leading the clinical development of Acer’s two lead programs, ACER-001 and ACER-002. “Bob brings a unique perspective […]
Read More